通过癌症特异性泛素结合酶降解AMPK
Carlos T Pineda1, Saumya Ramanathan1, Klementina Fon Tacer1
1Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|February 14, 2015
概括
癌细胞通过劫持涉及MAGE-A3/6-TRIM28.28的生殖系机制来抑制AMP激活蛋白激酶 (AMPK). 这导致AMPKα1降解,促进癌症生长和对向AMPK的药物的敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞的新陈代谢
背景情况:
- AMP激活蛋白激酶 (AMPK) 是细胞能量恒温的关键调节者,抑制了合成代谢过程,并在代谢压力期间促进了代谢.
- 癌细胞可以通过各种机制逃避AMPK的增长限制功能,包括上游调节激酶的突变.
- MAGE-A3和MAGE-A6是通常仅限于男性生殖系的蛋白质,但在人类癌症中经常被重新激活,在那里它们对瘤细胞活力至关重要.
研究的目的:
- 阐明癌细胞抑制AMPK活动的新机制.
- 为了确定MAGE-A3 / 6-TRIM28在癌症中的全素结合酶复合物的特定标和功能.
- 了解AMPK抑制对癌症进展和治疗策略的影响.
主要方法:
- 使用查试验来识别MAGE-A3/6-TRIM28泛素化酶复合物的标.
- 进行了泛化试验,以确认MAGE-A3/6-TRIM28.2直接向AMPKα1.
- 评估AMPKα1降解对自,mTOR信号传递和细胞对甲胺等AMPK激动剂的反应的功能后果.
主要成果:
- 确定了MAGE-A3/6-TRIM28作为一种全方位合酶,该合酶特别准并降解AMPKα1.1.
- 证明MAGE-A3 / 6-介导的AMPKα1降解导致自的抑制.
- 表明抑制AMPK会导致mTOR通路的激活,并增加癌细胞对AMPK激动剂的敏感性.
结论:
- 癌症中普遍存在的一种机制是通过MAGE-A3/6-TRIM28介导的AMPKα1.1的全域化和降解来抑制AMPK.
- 这种被劫持的生殖系机制通过抑制瘤抑制途径 (如自) 来促进癌细胞的活力.
- 针对这种MAGE-A3/6-TRIM28-AMPK轴可能是对表现出MAGE-A3/6再表达的癌症的有希望的治疗策略.
相关概念视频
Regulated Protein Degradation
9.4K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.4K
PI3K/mTOR/AKT Signaling Pathway
6.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression
1.8K
1.8K
The Proteasome
2.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K
The Proteasome
10.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.7K


